On June 3, 2026 Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, reported that it will participate in a virtual fireside chat hosted by Cantor on June 8, 2026 at 12:00 p.m. ET. The event will feature the Company’s senior management team and Robert Coleman, MD, FACOG, FACS, a globally recognized gynecologist oncologist and Principal Investigator of the Phase 3 XPORT-EC-042 trial.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Institutional investors interested in attending the live event should contact their Cantor representative. A replay of this event will be available on June 8, 2026 at approximately 2:00pm ET under "Events and Presentations" in the Investors & Media section of the Company’s website.

(Press release, Karyopharm, JUN 3, 2026, View Source,-2026 [SID1234666407])